Five-year safety and growth response of long-acting PEGylated recombinant human growth hormone in children with growth hormone deficiency-data from CGLS database.

Plain-language guide to PMID 40542826 (2025): observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 1,207 participants.

Key Facts

PMID: 40542826
Journal: European journal of pediatrics
Year: 2025
Study type: Observational Study
Authors: Wu W et al. (36 authors)
DOI: 10.1007/s00431-025-06268-5

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.

Growth hormone deficiency (GHD) is an endocrine disorder characterized by insufficient production of growth hormone (GH).

In this study, the researchers evaluated the safety profile and five-year growth response of PEG-rhGH based on the data from the CGLS database in participants with PGHD in China.

Who Took Part

The study group was 1,207 participants.

The age groups tagged for this paper are young children, children and teenagers, both men and women.

In this real-world registry-based observational study, a total of 1,207 participants were included in the safety analysis set.

What Was Measured

In this study, the researchers evaluated the safety profile and five-year growth response of PEG-rhGH based on the data from the CGLS database in participants with PGHD in China.

Key outcomes assessed comprised adverse events (AEs), serious AEs (SAEs), and height gain.

The subject headings attached to it are Human Growth Hormone, China, Recombinant Proteins, Registries, Body Height, Databases, Factual and Growth Disorders.

The authors tagged it with the keywords CGLS database, Growth response, PEG-rhGH and Safety.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 1,207 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 1 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (European journal of pediatrics), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.